Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients

NCT ID: NCT06373744

Last Updated: 2024-04-18

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 597 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-01-01
• Study Completion Date: 2024-01-01

Brief Summary

The goal of this observational study is to learn about the effects of metronomic chemotherapy in advanced breast cancer patients. The main question it aims to answer is:

How effective is metronomic chemotherapy in advanced breast cancer? Specific benefit groups of metronomic chemotherapy.

Conditions

Breast Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

metronomic chemotherapy

Patients with advanced breast cancer who received metronomic chemotherapy.

cyclophosphamide , methotrexate , vinorelbine ,capecitabine

Intervention Type: DRUG

The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine

Interventions

cyclophosphamide , methotrexate , vinorelbine ,capecitabine

The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Females, >18 years old;

2. Diagnosed with advanced breast cancer when using metronomic chemotherapy;

3. At least one clinical evaluation, including physical examination and imaging, according to the instructions of the supervising physician during the use of metronomic chemotherapy. Examinations include ultrasound, computed tomography, and magnetic resonance imaging;

4. Metronomic chemotherapy can be used alone, and patients who use it in combination with other drugs can also be included;

5. The clinical pathological information that needs to be collected is complete.

Exclusion Criteria

1. Taking the drug for less than 2 weeks;

2. losing follow-up after taking the therapy;

3. The patient's breast cancer was still in the early stage when taking the therapy.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

wang shusen

Dr

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Shusen Wang, MD

Role: PRINCIPAL_INVESTIGATOR

Sun Yat-sen University

Locations

Shusen Wang

Guangzhou, Gangdong, China

Countries

China

Other Identifiers

SYSU-022

Identifier Type: -

Identifier Source: org_study_id